Dataset related to article "Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcome, Toxicity and Predictive Factors in Patients Treated with Hypofractionated Sequential or Exclusive Radiotherapy "

This record contains raw data related to article “Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcome, Toxicity and Predictive Factors in Patients Treated with Hypofractionated Sequential or Exclusive Radiotherapy" Abstract: <strong>Background: </strong> This study evaluated the outcome, toxicity and predictive factors in patients unfit for concurrent chemo-radiotherapy (CT-RT) treated with hypofractionated sequential CT-RT or exclusive radiotherapy (RT) for locally advanced non-small cell lung cancer (LA-NSCLC). <strong>Methods: </strong> We included patients affected by LA-NSCLC (stage IIA-IVA) treated with a total dose of 50-60 Gy in 20 fractions. The primary outcomes were local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS) and overall survival (OS). Univariate analysis was used to correlate outcomes with prognostic factors. <strong>Results: </strong> Between 2011 and 2019, 210 patients were treated, 113 (53.8%) with sequential CT-RT and 97 (46.2%) with exclusive RT. After a median follow-up of 15.3 months, 74 patients (35.2%) had a local progression and 133 (63.3%) had a distant progression. The one-, two- and five-year LC were 73.6%, 55.3% and 47.9%, respectively. At the time of analysis, 167 patients (79.5%) died. The one-, two- and five-year OS were 64.7%, 36% and 20%, respectively. PTV volume correlated with PFS (<em>p</em> = 0.001) and LC (<em>p</em> = 0.005). Acute and late toxicity occurred in 82% and 26% of patients. <strong>Conclusions: </strong> Albeit with the known limitations of a retrospective and heterogeneous study, our work shows that hypofractionated sequential CT-RT or exclusive RT offer a good local control and toxicity profile and a promising survival rate in LA-NSCLC patients unfit for the concurrent CT-RT scheme.本数据集包含与题为《局部晚期非小细胞肺癌：采用低分割序贯放化疗或单纯放疗治疗患者的临床结局、毒性及预测因素》的学术论文相关的原始数据。摘要：<strong>背景：</strong> 本研究针对无法耐受同步放化疗（concurrent chemo-radiotherapy, CT-RT）的局部晚期非小细胞肺癌（locally advanced non-small cell lung cancer, LA-NSCLC）患者，评估其接受低分割序贯放化疗或单纯放疗（exclusive radiotherapy, RT）后的临床结局、毒性反应及预测因素。<strong>方法：</strong> 本研究纳入2011年至2019年间确诊为IIA~IVA期局部晚期非小细胞肺癌、接受总剂量50~60 Gy、分20次分割照射的患者。主要研究终点包括局部控制率（local control, LC）、无远处转移生存期（distant metastasis-free survival, DMFS）、无进展生存期（progression-free survival, PFS）及总生存期（overall survival, OS）。采用单因素分析探究患者结局与预后因素的相关性。<strong>结果：</strong> 2011至2019年间共纳入210例患者，其中113例（53.8%）接受序贯放化疗，97例（46.2%）接受单纯放疗。中位随访时间为15.3个月，74例（35.2%）患者出现局部进展，133例（63.3%）出现远处进展。1年、2年及5年局部控制率分别为73.6%、55.3%及47.9%。截至数据分析时，167例（79.5%）患者死亡。1年、2年及5年总生存率分别为64.7%、36%及20%。计划靶区（planning target volume, PTV）体积与无进展生存期（p = 0.001）及局部控制率（p = 0.005）具有显著相关性。急性毒性反应与晚期毒性反应的发生率分别为82%及26%。<strong>结论：</strong> 尽管本研究存在回顾性及异质性研究的固有局限性，但结果显示，对于无法耐受同步放化疗方案的局部晚期非小细胞肺癌患者，采用低分割序贯放化疗或单纯放疗可获得良好的局部控制效果与安全性，且生存率表现可观。